Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by longrun86on Feb 05, 2021 2:40pm
264 Views
Post# 32486405

Prospectus & Event Catalyst

Prospectus & Event CatalystThis morning I decided to take a position in Knight. I like the price, the strategy, and Management's alignment through share ownership.

My hope is that all of the impatient shareholders have moved on and only those with a long term view are left standing!

The short form prospectus is interesting in that it allows for a combination of debt and equity. While the time horizon is 25 months, I am hoping there will be an event prior to that which is likely dependant on a resolution to Covid and Management's ability to travel.

I am by no means an expert in pharmaceutical drugs but am looking forward to learning a lot more along the way so please feel free to share resources that you think a person with a "non-scientific" background would benefit from.

Best of luck,

LR
<< Previous
Bullboard Posts
Next >>